Tisotumab vedotin found efficacious for recurrent cervical cancer
Second- or third-line treatment with tisotumab vedotin is efficacious for patients with recurrent cervical cancer, according to a study published in the New England Journal of Medicine.
Jul 8, 2024
0
0